2023-2024 Regular SessionMassachusetts Legislature

S2520

Legislative Summary

Relative to pharmaceutical access, costs and transparency

Bill History

11/15/2023
Reported from the committee on Senate Bills in the Third Reading
Senate
11/15/2023
New draft of S2499
Senate
11/15/2023
Passed to be engrossed -see Roll Call #99 (Yeas 39 to Nays 0)
Senate
11/20/2023
Read; and referred to the committee on House Ways and Means
House of Representatives
7/22/2024
Committee recommended ought to pass with an amendment, substituting the text of an amendment, see H4891
House of Representatives
7/22/2024
Referred to the committee on House Steering, Policy and Scheduling with the amendment pending
House of Representatives
7/24/2024
Committee reported that the matter be placed in the Orders of the Day for the next sitting with the amendment pending
House of Representatives
7/24/2024
Read second
House of Representatives
7/24/2024
Amendment (as recommended by the committee on House Ways and Means) adopted
House of Representatives
7/24/2024
Ordered to the third reading
House of Representatives
7/24/2024
Rules suspended
House of Representatives
7/24/2024
Read third
House of Representatives
7/24/2024
Amended by substitution of a new text (see H4910)
House of Representatives
7/24/2024
Passed to be engrossed - 158 YEAS to 0 NAYS (See YEA and NAY No. 142 )
House of Representatives
7/25/2024
Rules suspended
Senate
7/25/2024
Senate NON-concurred in the House amendment
Senate
7/25/2024
Committee on conference (Friedman-Cronin-Tarr), appointed
Senate
7/25/2024
House insisted on its amendment
House of Representatives
7/25/2024
Committee of conference appointed - (Lawn-F. Moran-Barrows), in concurrence
House of Representatives

Roll Call Votes

Senate Engrossed Roll Call #99
11/15/2023
39
Yea
0
Nay
0
Not Voting
0
Absent
Result: PASSED